SpringerLink
Log in

Effets antiangiogéniques dans le traitement des hémopathies malignes

The effect of angiogenesis inhibitors in the treatment of malignant blood disorders

  • Mise au Point / Update
  • Published:
Oncologie

Abstract

Angiogenesis is recognised as amajor factor in the development of solid tumours and it is only recently that similar mechanisms have been described in haematological neoplasms. Expression of angiogenic peptides such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) is closely correlated with clinical aspects of large cell non-Hodgkin lymphoma (NHL). Inmultiple myeloma, microvessel density (MVD) is an independent marker for overall survival. These results have encouraged not only the development of drugs, such as lenalidomide, capable of blocking proangiogenic cytokines indiscriminately, but also that of more specific anti-VEGF agents. This reviewdiscusses current knowledge of angiogenesis, its physiological aspects and implications in the treatment of haematological neoplasms. Combination chemotherapy incorporating these novel drugs to obtain optimal responses as well as their use within stem-cell therapy remains to be discussed.

Résumé

Le rôle de l’angiogenèse est reconnu comme important dans les tumeurs solides, et ce n’est que récemment que les mêmes phénomènes ont été décrits dans les hémopathies malignes. L’expression des peptides angiogéniques comme le vascular endothelial growth factor (VEGF) et le basic fibroblast growth factor (bFGF) est corrélée avec la présentation clinique des lymphomes non hodgkiniens à grandes cellules. La densité en microvaisseaux dans le myélome multiple est un marqueur indépendant de survie. Tous ces résultats ont encouragé le développement de médicaments bloquant de manière large les cytokines proangiogéniques, comme le lénalidomide, mais aussi d’agents ciblés anti-VEGF. Cette revue reprend les connaissances sur l’angiogenèse qui permettent de nouvelles ouvertures sur la physiologie et le traitement des hémopathies malignes. La problématique est maintenant de combiner les chimiothérapies avec ces nouvelles molécules pour obtenir lesmeilleurs résultats possibles et de les positionner par rapport à la greffe de moelle.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Aguayo A (2004) The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep 3(3): 184–191

    PubMed  Google Scholar 

  2. Alexandrakis mg, Passam FH, Pappa CA, et al. (2005) Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 18(2): 287–295

    PubMed  CAS  Google Scholar 

  3. Badoux XC, Keating MJ, Wen S, et al. (2011) Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21725050

  4. Brunner B, Gunsilius E, Schumacher P, et al. (2002) Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 11(1): 119–125

    Article  PubMed  CAS  Google Scholar 

  5. Buckstein R, Kuruvilla J, Chua N, et al. (2011) Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multi-center study of the NCIC Clinical Trials Group. Leuk Lymphoma 52(5): 833–841

    Article  PubMed  CAS  Google Scholar 

  6. Chesi M, Brents LA, Ely SA, et al. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97(3): 729–736

    Article  PubMed  CAS  Google Scholar 

  7. Dimopoulos M, Spencer A, Attal M, et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21): 2123–2132

    Article  PubMed  CAS  Google Scholar 

  8. Dimopoulos MA, Chen C, Spencer A, et al. (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11): 2147–2152

    Article  PubMed  CAS  Google Scholar 

  9. Dunleavy K, Pittaluga S, Czuczman MS, et al. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113(24): 6069–6076

    Article  PubMed  CAS  Google Scholar 

  10. Facon T, Mary JY, Hulin C, et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594): 1209–1218

    Article  PubMed  CAS  Google Scholar 

  11. Fiedler W, Serve H, Döhner H, et al. (2005) A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3): 986–993

    Article  PubMed  CAS  Google Scholar 

  12. Fowler N, Hagemeister F, Mc Laughlin P, et al. (2011) Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-hodgkins lymphoma. In: Ann Oncol 22: abstr 137. Lugano (Switzerland); 2011

  13. Glasmacher A, Hahn C, Hoffmann F, et al. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132(5): 584–593

    Article  PubMed  CAS  Google Scholar 

  14. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. (2011) Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21495023

  15. Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1): 309–313

    PubMed  CAS  Google Scholar 

  16. Ikezoe T, Nishioka C, Tasaka T, et al. (2006) The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5(10): 2522–2530

    Article  PubMed  CAS  Google Scholar 

  17. Jagannath S, Barlogie B, Berenson J, et al. (2004) A phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2): 165–172

    Article  PubMed  CAS  Google Scholar 

  18. Legros L, Slama B, Karsenti J-M, et al. (2011) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Ann Hematol 91(1):39–46

    Article  PubMed  Google Scholar 

  19. Lentzsch S, LeBlanc R, Podar K, et al. (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17(1): 41–44

    Article  PubMed  CAS  Google Scholar 

  20. Lenz G, Wright G, Dave SS, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22): 2313–2323

    Article  PubMed  CAS  Google Scholar 

  21. List A, Dewald G, Bennett J, et al. (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14): 1456–1465

    Article  PubMed  CAS  Google Scholar 

  22. List A, Kurtin S, Roe DJ, et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6): 549–557

    Article  PubMed  CAS  Google Scholar 

  23. Mateos M-V, Richardson PG, Schlag R, et al. (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA Trial. J Clin Oncol 28(13): 2259–2266

    Article  PubMed  CAS  Google Scholar 

  24. Moreau P, Avet-Loiseau H, Facon T, et al. (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21849487

  25. Nowakowski G, Reeder C, Laplant B, et al. (2011) Combination of lenalidomide with R-CHOP (R2CHOP) is safe and effective as initial therapy for aggressive B-cell lymphomas — a phase I/II study. In: Ann Oncol 22: abstr 110. Lugano (Switzerland); 2011

  26. Palumbo A, Bringhen S, Caravita T, et al. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513): 825–831

    Article  PubMed  CAS  Google Scholar 

  27. Palumbo A, Dimopoulos M, Delforge M (2010) A phase III study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >65 years with newlydianosed multiple myeloma (NDMM) [abstract]. Haematologica 95(suppl 2)

  28. Rajkumar SV, Blood E, Vesole D, et al. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3): 431–436

    Article  PubMed  CAS  Google Scholar 

  29. Rajkumar SV, Jacobus S, Callander NS, et al. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1): 29–37

    Article  PubMed  CAS  Google Scholar 

  30. Rajkumar SV, Leong T, Roche PC, et al. (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6(8): 3111–3116

    PubMed  CAS  Google Scholar 

  31. Raza A, Reeves JA, Feldman EJ, et al. (2008) Phase II study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111(1): 86–93

    Article  PubMed  CAS  Google Scholar 

  32. Reeder CB, Ansell SM (2011) Novel therapeutic agents for B-cell lymphoma: develo** rational combinations. Blood 117(5): 1453–1462

    Article  PubMed  CAS  Google Scholar 

  33. Richardson PG, Barlogie B, Berenson J, et al. (2003) A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26): 2609–2617

    Article  PubMed  CAS  Google Scholar 

  34. Richardson PG, Sonneveld P, Schuster MW, et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24): 2487–2498

    Article  PubMed  CAS  Google Scholar 

  35. Richardson PG, Blood E, Mitsiades CS, et al. (2006) A randomized phase II study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108(10): 3458–3464

    Article  PubMed  CAS  Google Scholar 

  36. Ruan J, Hajjar K, Rafii S, Leonard JP (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Ann Oncol 20(3): 413–424

    Article  PubMed  CAS  Google Scholar 

  37. Singhal S, Mehta J, Desikan R, et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21): 1565–1571

    Article  PubMed  CAS  Google Scholar 

  38. Stopeck AT, Unger JM, Rimsza LM, et al. (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma 50(5): 728–735

    Article  PubMed  CAS  Google Scholar 

  39. Vacca A, Ribatti D, Roncali L, et al. (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87(3): 503–508

    Article  PubMed  CAS  Google Scholar 

  40. Wang L, Shi W-Y, Yang F, et al. (2011) Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells. Haematologica 96(6): 927–931

    Article  PubMed  Google Scholar 

  41. Wang M, Fayad L, Wagner-Bartak N, et al. (2011) Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. In: Ann Oncol 22: abtr 109. Lugano (Switzerland)

  42. Weber DM, Chen C, Niesvizky R, et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21): 2133–2142

    Article  PubMed  CAS  Google Scholar 

  43. Witzig TE, Vose JM, Zinzani PL, et al. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22(7): 1622–1627

    Article  PubMed  CAS  Google Scholar 

  44. Zhao W-L, Mourah S, Mounier N, et al. (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 84(11): 1512–1519

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncohématologie, CHU de Nice, l’Archet, 151, route de Saint-Antoine-Ginestière, F-06000, Nice, France

    N. Martis & N. Mounier

Authors
  1. N. Martis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Mounier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Martis.

About this article

Cite this article

Martis, N., Mounier, N. Effets antiangiogéniques dans le traitement des hémopathies malignes. Oncologie 14, 257–263 (2012). https://doi.org/10.1007/s10269-012-2147-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-012-2147-8

Keywords

Mots clés

Search

Navigation